Lichen Planopilaris
Clinical guidelines for managing primary cicatricial scarring alopecia, evaluating follicular stem cell damage, and reviewing local steroids, Hydroxychloroquine, and JAK inhibitors.
Table of Contents
π§ Standard of Care & Symptoms
Lichen Planopilaris (LPP) is a primary lymphocytic cicatricial (scarring) alopecia that results in permanent, irreversible hair loss.
- Presentation: Unique follicular signs and scarring.
- Patchy Alopecia: Smooth, shiny patches of hair loss on the scalp (most commonly crown or vertex) with complete loss of follicular openings (ostia).
- Follicular Hyperkeratosis: Rough, keratotic scale and plugging (tubular casts) surrounding the base of active hair shafts at the patch margins.
- Perifollicular Erythema: Redness around the base of active hair follicles, signifying active lymphocytic inflammation.
- Subjective Symptoms: Patients frequently report intense itching (pruritus), burning, tenderness, or pain in the active zones of the scalp.
- Clinical Subtypes: Classic LPP, Frontal Fibrosing Alopecia (FFA, characterized by progressive recession of the frontal and temporal hairline), and Graham-Little-Piccardi-Lassueur Syndrome.
𧬠Diagnostics & Bulge Stem Cell Attack
Diagnosis requires a detailed trichoscopic evaluation and confirmation via a scalp punch biopsy of an active margin.
- Trichoscopy (Dermoscopy of Scalp): Reveals perifollicular scale (tubular scaling), perifollicular erythema, white dots (fibrous tracts), and loss of follicular openings.
- Scalp Punch Biopsy (4mm): Taken from an active area displaying perifollicular scale. Histopathology shows:
- A dense, lichenoid (band-like) lymphocytic infiltrate targeting the **infundibulum and follicular bulge** regions of the outer root sheath.
- Vacuolar degeneration of the basal layer of the follicle and apoptotic keratinocytes (colloid/Civatte bodies).
- Concentric, lamellar perifollicular fibroplasia ("onion-skin" scarring) in late stages, replacing the follicle with a fibrous tract.
Pathogenesis & Bulge Stem Cell Destruction
The permanent nature of LPP hair loss is due to targeted autoimmune destruction of the regenerative machinery:
- Bulge Stem Cell Target: In healthy hair cycles, the **follicular bulge** contains slow-cycling epithelial stem cells responsible for regenerating the hair follicle. In LPP, a cell-mediated (T-lymphocyte) autoimmune attack specifically targets these bulge stem cells.
- Inability to Regenerate: Because the lymphocytic infiltrate destroys the bulge stem cell reservoir, the hair follicle cannot initiate new anagen (growth) cycles. Once the follicle is destroyed and replaced by fibrous scar tissue, hair regrowth is biologically impossible, making early intervention critical to save remaining hair.
π Corticosteroids, Hydroxychloroquine & JAK Blockade
Therapy focuses on halting the inflammatory progression and preserving existing hair. Regrowth of already scarred patches is not possible.
First-Line Local Therapy
- Ultra-Potent Topical Corticosteroids (Clobetasol Propionate 0.05%): Applied directly to active borders daily to reduce lymphocytic infiltration.
- Intralesional Corticosteroids: Triamcinolone acetonide (5-10 mg/mL) injected subdermally into active inflammatory areas every 4 to 6 weeks.
Systemic Maintenance Therapy
- Hydroxychloroquine: Antimalarial agent administered at 200 mg twice daily. Blocks antigen presentation and lysosomal pathways, stabilizing disease progression in up to 60-70% of patients over a 3-6 month period.
- Doxycycline: An tetracycline antibiotic used for its anti-inflammatory and matrix metalloproteinase (MMP) inhibitor properties.
Systemic JAK Inhibitors (Refractory/Rapid Cases)
- JAK Inhibitors (e.g., Tofacitinib, Baricitinib): Block JAK-STAT signaling pathways to suppress interferon-gamma production, showing high rates of inflammatory stabilization in rapidly progressive cases.
π¬ Active Clinical Trials
Clinical trials are currently evaluating selective JAK-1/3 inhibitors, low-dose oral naltrexone as an anti-inflammatory adjunct, and platelet-rich plasma (PRP) injections to stabilize tissue microenvironments.
A randomized controlled trial testing the efficacy of baricitinib in halting scalp inflammation and follicular scarring.
Key Inclusion: Age 18 to 70, biopsy-confirmed active classic Lichen Planopilaris or Frontal Fibrosing Alopecia, with baseline LPP Activity Index (LPPAI) ≥ 4.Evaluating whether low-dose naltrexone downregulates glial cell activation and microglial inflammation to reduce scalp pain and itch.
Key Inclusion: Age ≥ 18, active symptomatic LPP, experiencing moderate to severe scalp pain or itching.Comparing the anti-inflammatory and tissue healing outcomes of autologous PRP infusions versus triamcinolone injections.
Key Inclusion: Age 18 to 65, active classic LPP, displaying perifollicular scale.πΊοΈ Next Steps After Diagnosis
If you have recently been diagnosed with Lichen Planopilaris, coordinate these care pathways:
- Perform a Scalp Biopsy: Confirm that the hair loss is a lymphocytic scarring form (LPP) rather than a non-scarring form like alopecia areata.
- Initiate Local Steroids: Start clobetasol ointment or schedule intralesional steroid injections to immediately cool down active inflammation.
- Discuss Hydroxychloroquine: If inflammation is widespread or spreading, consult your dermatologist about starting hydroxychloroquine (requires baseline eye exam).
- Avoid Scalp Trauma: Avoid harsh chemical treatments, tight hairstyles, or heavy heat tools, which can accelerate follicle loss.
β Patient FAQ
Q: Will my hair grow back in the areas where it has been lost?
A: Unfortunately, no. In Lichen Planopilaris, the immune system destroys the stem cells in the **follicular bulge**, which are required to grow new hair. Once these cells are destroyed, the hair follicle is permanently replaced by scar tissue. The goal of all LPP treatments is to save the hair you currently have by halting the spread of the disease; they cannot restore hair in patches that are already smooth and scarred.
Q: How long does it take for treatments to start working?
A: LPP is a slow-moving but persistent disease, and treatments take time to stabilize the immune system. Systemic medications like Hydroxychloroquine typically require 3 to 6 months of daily use before you will notice a reduction in scalp itching, burning, or hair shedding. It is vital to continue your medications consistently even if you do not see immediate improvement.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.